ELOXX PHARMACEUTICALS, INC. Accounts Payable
ELOXX PHARMACEUTICALS, INC. (ELOX) had Accounts Payable of $3.03 million as of 2026-06-30, per its S-1 filed 2026-09-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-09-11
- 2026-06-30: Accounts Payable, Current $3.03M.
- 2026-03-31: Accounts Payable, Current $3.03M.
- 2025-12-31: Accounts Payable, Current $2.71M.
- 2024-12-31: Accounts Payable, Current $5.35M.
| Period end | Accounts Payable, Current | Accounts Payable, Current as first filed |
|---|---|---|
| 2026-06-30 | $3.03M S-1 · filed 2026-09-11 | |
| 2026-03-31 | $3.03M S-1/A · filed 2026-06-04 | |
| 2025-12-31 | $2.71M S-1 · filed 2026-09-11 | |
| 2024-12-31 | $5.35M S-1 · filed 2026-09-11 | |
| 2023-12-31 | $5.70M S-1 · filed 2026-09-11 | |
| 2023-09-30 | $3.13M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $3.12M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $2.43M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $3.02M 10-Q · filed 2023-11-13 | |
| 2022-09-30 | $1.59M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $1.93M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $2.90M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $1.38M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $2.51M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $2.02M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $485.00K 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $481.00K 10-K · filed 2022-03-30 | |
| 2020-09-30 | $638.00K 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $770.00K 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $1.39M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $1.87M 10-K · filed 2021-03-12 | |
| 2019-09-30 | $1.69M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $2.47M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $2.24M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $747.00K 10-K · filed 2020-03-06 | |
| 2018-09-30 | $1.35M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $2.10M 10-Q · filed 2018-08-10 | |
| 2018-03-31 | $2.17M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $1.53M 10-K · filed 2019-03-14 | |
| 2017-09-30 | $108.57K 10-Q · filed 2017-11-14 | |
| 2017-06-30 | $191.60K 10-Q · filed 2017-11-14 | |
| 2017-03-31 | $109.15K 10-Q · filed 2017-05-22 | |
| 2016-12-31 | $1.90M 10-K · filed 2018-03-16 | $193.94K 10-Q · filed 2017-02-10 |
| 2016-09-30 | $144.87K 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $90.31K 10-K · filed 2017-10-13 | |
| 2016-03-31 | $56.60K 10-Q · filed 2016-05-12 | |
| 2015-12-31 | $63.50K 10-Q · filed 2016-02-16 | |
| 2015-09-30 | $174.36K 10-Q · filed 2015-11-16 | |
| 2015-06-30 | $232.03K 10-K · filed 2016-10-13 | |
| 2015-03-31 | $656.47K 10-Q · filed 2015-05-14 | |
| 2014-12-31 | $1.31M 10-Q · filed 2015-02-17 | |
| 2014-09-30 | $613.02K 10-Q · filed 2014-11-14 | |
| 2014-06-30 | $901.18K 10-K · filed 2015-10-09 | |
| 2014-03-31 | $324.94K 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $477.63K 10-Q · filed 2014-02-14 | |
| 2013-09-30 | $1.00M 10-Q · filed 2013-11-14 | |
| 2013-06-30 | $637.32K 10-K · filed 2014-09-29 | |
| 2013-03-31 | $686.95K 10-Q · filed 2013-05-15 | |
| 2012-12-31 | $1.09M 10-Q · filed 2013-02-14 | |
| 2012-09-30 | $932.17K 10-Q · filed 2012-11-14 | |
| 2012-06-30 | $594.51K 10-K · filed 2013-09-11 | |
| 2012-03-31 | $804.78K 10-Q · filed 2012-05-14 | |
| 2011-12-31 | $443.75K 10-Q · filed 2012-02-14 | |
| 2011-09-30 | $949.09K 10-Q · filed 2011-11-14 | |
| 2011-06-30 | $559.52K 10-K/A · filed 2012-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |